X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4763) 4763
Newsletter (586) 586
Book Review (499) 499
Publication (252) 252
Conference Proceeding (37) 37
Newspaper Article (29) 29
Magazine Article (20) 20
Book Chapter (11) 11
Dissertation (8) 8
Paper (7) 7
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rosuvastatin (3865) 3865
index medicus (3193) 3193
humans (2754) 2754
male (1944) 1944
rosuvastatin calcium (1857) 1857
statins (1633) 1633
female (1598) 1598
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1350) 1350
middle aged (1316) 1316
atorvastatin (1139) 1139
aged (1014) 1014
cardiac & cardiovascular systems (999) 999
fluorobenzenes - therapeutic use (988) 988
antilipemic agents (987) 987
cholesterol (962) 962
pharmacology & pharmacy (957) 957
sulfonamides - therapeutic use (943) 943
pyrimidines - therapeutic use (940) 940
simvastatin (740) 740
treatment outcome (698) 698
research (674) 674
adult (647) 647
risk factors (633) 633
animals (627) 627
atherosclerosis (566) 566
cholesterol, ldl - blood (548) 548
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (545) 545
pravastatin (518) 518
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (510) 510
abridged index medicus (488) 488
risk (478) 478
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (471) 471
prevention (471) 471
therapy (460) 460
analysis (458) 458
c-reactive protein (457) 457
drug therapy (443) 443
hypercholesterolemia (439) 439
lipids (435) 435
care and treatment (434) 434
medicine, general & internal (434) 434
fluorobenzenes - pharmacology (432) 432
cardiovascular (415) 415
sulfonamides - pharmacology (415) 415
cardiovascular disease (413) 413
pyrimidines - pharmacology (413) 413
fluorobenzenes - administration & dosage (412) 412
atorvastatin calcium (406) 406
dosage and administration (392) 392
pyrimidines - administration & dosage (391) 391
sulfonamides - administration & dosage (389) 389
coronary-heart-disease (370) 370
statin (366) 366
hypercholesterolemia - drug therapy (362) 362
inflammation (356) 356
peripheral vascular disease (348) 348
disease (343) 343
cardiovascular diseases (337) 337
cardiovascular diseases - prevention & control (337) 337
low density lipoproteins (333) 333
rats (326) 326
mortality (321) 321
pharmacokinetics (314) 314
medical research (312) 312
safety (309) 309
statin therapy (308) 308
dose-response relationship, drug (307) 307
efficacy (307) 307
cardiovascular-disease (305) 305
fluorobenzenes - adverse effects (287) 287
health aspects (287) 287
metaanalysis (287) 287
clinical trials (282) 282
medicine, experimental (281) 281
pyrimidines - adverse effects (277) 277
sulfonamides - adverse effects (277) 277
anticholesteremic agents - therapeutic use (272) 272
coronary heart disease (266) 266
cardiovascular agents (262) 262
drug therapy, combination (256) 256
density-lipoprotein cholesterol (254) 254
diabetes (250) 250
prospective studies (250) 250
double-blind method (249) 249
heptanoic acids - therapeutic use (249) 249
pyrroles - therapeutic use (248) 248
ezetimibe (247) 247
primary prevention (246) 246
randomized controlled trials as topic (245) 245
trial (245) 245
cardiology (244) 244
events (241) 241
time factors (239) 239
aged, 80 and over (238) 238
heart failure (236) 236
biomarkers - blood (232) 232
nutritional and metabolic diseases (232) 232
cardiac patients (230) 230
dyslipidemia (223) 223
oxidative stress (218) 218
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5157) 5157
Russian (89) 89
Chinese (31) 31
Spanish (28) 28
German (23) 23
French (20) 20
Italian (18) 18
Japanese (12) 12
Hungarian (9) 9
Portuguese (7) 7
Swedish (7) 7
Korean (6) 6
Polish (6) 6
Turkish (6) 6
Czech (5) 5
Dutch (5) 5
Ukrainian (5) 5
Croatian (4) 4
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Epilepsy Research, ISSN 0920-1211, 2017, Volume 135, pp. 64 - 70
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 05/2018, Volume 27, Issue 9, pp. 1058 - 1064
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 329 - 340
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 244, pp. 138 - 146
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 341 - 355
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure... 
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9792, pp. 684 - 692
Summary Background The JUPITER trial showed that some patients with LDL-cholesterol concentrations less than 3·37 mmol/L (<130 mg/dL) and high-sensitivity... 
Internal Medicine | ALL-CAUSE MORTALITY | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | MEN | TRIAL EVALUATING ROSUVASTATIN | RISK | SUBCLINICAL ATHEROSCLEROSIS | INTERVENTION | COMPUTED-TOMOGRAPHY | PRIMARY PREVENTION | Calcium - metabolism | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Coronary Vessels - metabolism | Coronary Disease - metabolism | Aged, 80 and over | Cholesterol, LDL - blood | Female | C-Reactive Protein - analysis | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - metabolism | Risk Assessment | Coronary Artery Disease - metabolism | Risk Factors | Coronary Artery Disease - prevention & control | Rosuvastatin Calcium | Coronary Disease - diagnosis | Coronary Disease - prevention & control | Sulfonamides - therapeutic use | Coronary Artery Disease - diagnosis | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Survival Analysis | Aged | Fluorobenzenes - therapeutic use | C-reactive protein | Physiological aspects | Rosuvastatin | Research | Cardiovascular diseases | Drug therapy | Health aspects | Heart attacks | Mortality | Risk assessment | Atherosclerosis | Colleges & universities | Cardiovascular disease | Triglycerides | Cost control | Index Medicus | Abridged Index Medicus | Calcification (ectopic) | Heart | mesas | Calcium | Lung | Clinical trials | Population studies | Coronary heart disease | Blood